Scott M Rocklage
CIK 1219014 · last filed 2024-03-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SCPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4 EMBARCADERO CENTER, SUITE 3110
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLYB | 10%+ Owner | 156,469 | $16.65 | $2.61M | -$19.72M | 2 | 2023-03-09 |
| Pear Therapeutics, Inc. (PEARW) Delisted | 10%+ Owner | 537,406 | $0.01 | $3.2K | -$2.31M | 1 | 2022-11-15 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 3,153,331 | $13.29 | $41.91M | -$50.76M | 1 | 2020-12-31 |
| APRE | Director | 3,798 | $0.45 | $1.7K | -$20.01M | 5 | 2020-07-01 |
| CABA | 10%+ Owner | 3,214,721 | $1.35 | $4.34M | $35.00M | 1 | 2019-10-31 |
| IDYA | 10%+ Owner | 84,420 | $32.88 | $2.78M | $37.50M | 1 | 2019-05-28 |
| ARVN | 10%+ Owner | 4,512,136 | $7.31 | $32.98M | -$30.68M | 1 | 2019-04-01 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 4 | 2018-06-15 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 103,945 | $5.67 | $589.4K | $55.00M | 1 | 2017-11-21 |
| PULM | Director | 844 | $1.44 | $1.2K | $266.8K | 4 | 2016-02-25 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | 2,549,211 | — | — | $2.00M | 2 | 2015-06-08 |
| VIVEVE MEDICAL, INC. (TCON) Delisted | 10%+ Owner | 36,551 | $0.03 | $1.2K | $1.50M | 1 | 2015-05-29 |
| Achaogen, Inc. (AKAO) Delisted | Director | — | — | — | $0 | 1 | 2014-03-13 |
| Relypsa Inc (RLYP) Delisted | Director | 2,258,376 | — | — | $4.10M | 2 | 2013-11-20 |
Recent Filings · Page 3 of 3
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-25 | PULM | Grant (A) | — | $0 | EDGAR |
| 2015-06-17 | PULM | Mixed | +1,361,027 | $266.8K | EDGAR |
| 2015-06-11 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-08 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-29 | VIVEVE MEDICAL, INC. (TCON) Delisted | Buy (P) | +4,054,050 | $1.50M | EDGAR |
| 2015-02-06 | EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Buy (P) | +400,000 | $2.00M | EDGAR |
| 2014-03-13 | Achaogen, Inc. (AKAO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-11-20 | Relypsa Inc (RLYP) Delisted | Mixed | +4,792,796 | $4.00M | EDGAR |
| 2013-11-20 | Relypsa Inc (RLYP) Delisted | Mixed | +30,507 | $103.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.